anonymous
Guest
anonymous
Guest
saw that imaging was sold, almost given away from what I read. The rhetoric has started by preparing investors for the flat sales, low or no growth and keeping them sucked in. Further promising to evaluate businesses more in line with their strategy (bump it it high so they can dump it later before anyone catches on). Anyone have any information on what that means for pharma?